title: Effect of microencapsulation of Lactobacillus plantarum 25 into alginate/chitosan/alginate microcapsules on viability and cytokine induction.
abstract: Lactobacillus plantarum 25 (LP25) encapsulated into alginate/chitosan/alginate (ACA) microcapsules (LP25-ACA MCs) prepared by an extrusion methods were characterized to assess their efficacy in oral delivery. The particle sizes of LP25-ACA MCs were 1.11 +/- 0.32 mm. The loading content of LP25 was 1.11 x 10(7) colony forming unit (cfu)/microcapsule and encapsulation efficiency was above 98%. The viability of LP25 in ACA MCs was more than 65% in simulated gastric fluid (SGF, pH 2.0) and 75% in simulated small intestinal fluid (SIF, pH 7.2) up to 2 h. Encapsulated LP25 were completely released from LP25-ACA MCs in SIF and simulated colon fluid (SCF, pH 6.0) within 12 h and 8 h respectively. The viability of LP25 in ACA MCs till 5 weeks was above 58%, whereas viability of free LP25 stored at room temperature up to 5 weeks was zero. Besides, LP25-ACA MCs induced the secretion of tumor necrosis factor-alpha (TNF-alpha) and interleukin-6 (IL-6) from macrophages and dendritic cells showing the immunomodulatory effect of LP25. These findings demonstrate that the encapsulation of LP25 by ACA is a suitable strategy for oral delivery of probiotics.
authors.affiliation: Department of Agricultural Biotechnology, Seoul National University, Seoul 151-921, Republic of Korea.
authors.forename: Tao
authors.initials: T
authors.lastname: Jiang
authors.forename: You-Kyoung
authors.initials: YK
authors.lastname: Kim
authors.forename: Bijay
authors.initials: B
authors.lastname: Singh
authors.forename: Sang-Kee
authors.initials: SK
authors.lastname: Kang
authors.forename: Yun-Jaie
authors.initials: YJ
authors.lastname: Choi
authors.forename: Chong-Su
authors.initials: CS
authors.lastname: Cho
mesh_terms: D000284:Administration, Oral; D000464:Alginates / Q000737:chemistry*; D000818:Animals; D000900:Anti-Bacterial Agents / Q000008:administration & dosage; D002214:Capsules; D048271:Chitosan / Q000737:chemistry*; D016207:Cytokines / Q000378:metabolism*; D004339:Drug Compounding; D004926:Escherichia coli / Q000187:drug effects; D006801:Humans; D006863:Hydrogen-Ion Concentration; D015850:Interleukin-6 / Q000378:metabolism; D048191:Lactiplantibacillus plantarum; D008264:Macrophages / Q000166:cytology; D051379:Mice; D050296:Microbial Viability; D010316:Particle Size; D019936:Probiotics / Q000008:administration & dosage; D012486:Salmonella typhimurium / Q000187:drug effects; D013997:Time Factors; D014409:Tumor Necrosis Factor-alpha / Q000378:metabolism
chemical_list: D000464:Alginates; D000900:Anti-Bacterial Agents; D002214:Capsules; D016207:Cytokines; D015850:Interleukin-6; D014409:Tumor Necrosis Factor-alpha; D048271:Chitosan